Summary & Overview
CPT 90695: H5N8 Adjuvanted Cell-Culture Influenza Vaccine
CPT code 90695 denotes an adjuvanted, cell-culture–derived H5N8 influenza (avian flu) vaccine formulated for intramuscular injection. This code captures administration of a specialized pandemic or avian influenza vaccine product intended to boost immune response via an adjuvant. Nationally, recognition of this code matters for tracking vaccine utilization, ensuring correct billing for novel or pandemic influenza vaccines, and monitoring public health responses when H5N8 vaccines are deployed.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. The discussion addresses how the code is used across typical ambulatory vaccination sites and the administrative considerations for separately reportable intramuscular vaccine products.
Readers will find a concise overview of clinical context for H5N8 adjuvanted vaccines, common service settings, and what to expect in payer coverage conversations. The publication also outlines benchmarking and policy-relevant themes such as coding accuracy for novel influenza vaccines, implications for public health reporting, and gaps where data were not provided in the input. Data not available in the input will be identified explicitly in relevant sections.
Billing Code Overview
CPT code 90695 represents an H5N8 influenza (avian flu) virus vaccine product manufactured from cell cultures and formulated with an adjuvant to enhance immune response. The product is designed for intramuscular administration and is billed as a separately reportable intramuscular injection.
Service type: Vaccine administration (intramuscular), adjuvanted cell-culture influenza vaccine
Typical site of service: Clinic, physician office, outpatient vaccination center, or other ambulatory care settings where intramuscular vaccines are administered
Clinical & Coding Specifications
Clinical Context
A 58-year-old patient presents to a primary care clinic in the fall season for immunization against a novel H5N8 avian influenza strain. The vaccine product is a cell-culture–derived, adjuvanted intramuscular formulation administered as a single, separately reportable injection in the deltoid. The clinical workflow includes: pre-vaccination screening for contraindications (history of severe allergic reaction to prior influenza vaccines or vaccine components), documentation of informed verbal consent, verification of vaccine lot number and expiration, preparation of the intramuscular syringe, administration of the injection, observation for 15 minutes for immediate adverse reactions, and recording in the electronic health record and immunization registry. Billing staff assign 90695 for the vaccine. The modifier SH is applied when the administration is performed under the direction of a state health department program that supplies the vaccine. The typical site of service is an outpatient clinic, public health clinic, occupational health clinic, or designated vaccination site. Typical patient scenarios include adults at higher risk for influenza complications due to age or chronic conditions, healthcare workers requiring immunization, and individuals receiving vaccine as part of a public health immunization campaign.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
SH |